Compare BBLG & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBLG | SCNI |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.6M |
| IPO Year | N/A | N/A |
| Metric | BBLG | SCNI |
|---|---|---|
| Price | $1.74 | $0.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 878.7K | 34.8K |
| Earning Date | 02-27-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | N/A | ★ $1,147,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.28 |
| Revenue Growth | N/A | ★ 303.87 |
| 52 Week Low | $1.30 | $0.61 |
| 52 Week High | $7.74 | $6.18 |
| Indicator | BBLG | SCNI |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 48.47 |
| Support Level | $1.58 | $0.78 |
| Resistance Level | $1.88 | $0.96 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 66.00 | 56.47 |
Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.